Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial
|dc.identifier.citation||Krishnan, A. and Teixeira-Pinto, A. and Chan, D. and Chakera, A. and Dogra, G. and Boudville, N. and Irish, A. et al. 2017. Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial. Clinical Transplantation. 31 (10): pp. e13043.|
This is an 18-month prospective, randomized controlled trial (RCT) designed to compare the effect of early conversion from cyclosporin to everolimus/mycophenolic acid (E-MPA) between 3 and 4 months post-transplant to cyclosporin/mycophenolic acid (CsA-MPA) on left ventricular mass index (LVMI) at 3 and 18 months post-transplant (primary outcome). Secondary outcomes included estimated glomerular filtration rate (eGFR), viral infection, and adverse events. Twenty-four patients were randomized in a 1:1 ratio to E-MPA or CsA-MPA groups. There were no significant differences in mean (SD) LVMI at 3 (51.6±18.5 vs 53.7±15.7 g/m 2.7 ) and 18 months (52.7±16.3 vs 51.7±16.8 g/m 2.7 ) between CsA-MPA and E-MPA groups. The incidence of viral infections was reduced in E-MPA compared to CsA-MPA treatment groups (8% vs 50%, P=.02), but the incidences of acute rejection, adverse events, and drug discontinuation were similar between groups. There was an overall increase in eGFR with time (0.04 log- mL/min/1.73 m 2 per 6 months, P=.012) but no significant difference between the two groups across time (0.11 log- mL/min/1.73 m 2 , P=.311). Immunosuppressive regimen comprising early conversion from cyclosporine to everolimus was not associated with a regression of LVMI, but a lower risk of viral infections was observed.
|dc.title||Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial|
|curtin.department||Curtin Medical School|
|curtin.accessStatus||Fulltext not available|
Files in this item
There are no files associated with this item.